NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

重度憂鬱症 (MDD) - 市場考察,流行病學,市場預測:2030年

Major Depressive Disorder- Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 1023346
出版日期 按訂單生產 內容資訊 英文 350 Pages
商品交期: 2-10個工作天內
價格
重度憂鬱症 (MDD) - 市場考察,流行病學,市場預測:2030年 Major Depressive Disorder- Market Insight, Epidemiology and Market Forecast -2030
出版日期: 按訂單生產內容資訊: 英文 350 Pages
簡介

主要7個國家市場上重度憂鬱症 (MDD)的總患病人數,2020年是43,845,330人。

主要7個國家市場上重度憂鬱症 (MDD)的市場規模,2020年達到39億6,060萬美元,2018年∼2030年的年複合成長率,8.91%的成長估計。

本報告以重度憂鬱症 (MDD) 調查分析,以 美國、歐洲5個國家(德國,法國,義大利,西班牙,英國) 、日本的市場趨勢為焦點,提供過去、未來的流行病學,目前治療方法,新藥,市場規模等相關的系統性資訊。

目錄

第1章 主要考察

第2章 報告的簡介

第3章 重度憂鬱症 (MDD)的市場概要

  • 2018年的MDD的市場佔有率分佈
  • 2030年的MDD的市場佔有率分佈

第4章 重度憂鬱症 (MDD)的摘要整理

第5章 疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 類型
  • 原因
  • 憂鬱症的病理生理學
  • MDD的遺傳的基礎
  • 生物標記
  • 診斷和重病度

第6章 流行病學和患者族群

  • 主要調查結果
  • 主要7個國家的重度憂鬱症 (MDD)的12個月的總患病人數
  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第7章 治療和管理

第8章 MDD貢獻的組織

第9章 病患歷程

第10章 病例報告

第11章 上市藥

  • 主要競爭 - 上市藥
  • Brintellix:Takeda Pharmaceuticals
  • Fetzima:Forest Laboratories
  • Rexulti:Otsuka Pharmaceuticals
  • SPRAVATO (Esketamine):Janssen Research & Development

第12章 新藥

  • AXS-05:Axsome Therapeutics
  • Travivo:Fabre-Kramer Pharmaceuticals
  • SAGE-217:SAGE Therapeutics
  • VRAYLAR (Cariprazine):Allergan/Gedeon Richter
  • CTC-501:Chase Therapeutics
  • LY03005:Luye Pharma
  • MIN-202 (Seltorexant):Janssen Pharmaceuticals/Minerva Neurosciences
  • REL-1017:Relmada Therapeutics
  • PRAX-114:Praxis Precision Medicines
  • PDC-1421:BioLite Inc
  • PH10:VistaGen Therapeutics
  • AV-101:VistaGen Therapeutics
  • CAPLYTA (Lumateperone):Intra-Cellular Therapies

第13章 開發中止的藥

  • Pimavanserin:Acadia Pharmaceuticals
  • Rapastinel:Naurex (Allergan)

第14章 沒有開發報告

  • ALKS 5461:Alkermes
  • NRX-1074 (Apimostinel):Allergen

第15章 重度憂鬱症 (MDD) :主要7個市場分析

  • 主要調查結果
  • 的重度憂鬱症 (MDD)的市場規模主要7個國家

第16章 市場預測:各國

  • 美國:市場預測
  • 美國的市場規模
  • 歐洲5個國家:市場預測
  • 日本:市場預測

第17章 推動市場要素

第18章 市場障礙

第19章 SWOT分析

第20章 未滿足需求

第21章 市場進入

第22章 附錄

第23章 DelveInsight的服務內容

第24章 免責聲明

第25章 關於DelveInsight

目錄
Product Code: DIMI0314

DelveInsight's 'Major Depressive Disorder-Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

The Major Depressive Disorder market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Major Depressive Disorder symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Major Depressive Disorder symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018-2030

Major Depressive Disorder Disease Understanding and Treatment Algorithm

Major Depressive Disorder Overview

Major depressive disorder is a serious medical illness that disrupts a person's mood, behavior, thought processes, apart from degrading physical health. MDD does not have a single cause and can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or other risks.

In addition to the immediate symptoms of depression, MDD results in poor quality of life overall decreased productivity and can increase mortality from suicide. Social difficulties, including stigma, loss of employment, and marital conflict resulting from depression, can also occur. Anxiety Posttraumatic Stress Disorder (PTSD), and substance misuse are common co-occurring conditions that may worsen the existing depression and complicate treatment. Depression is considered a largely biological illness but can result from genetic, biological, environmental, and psychological factors. Trauma, loss of a loved one, a difficult relationship, or any stressful situation may trigger depression, but depression can also occur without an obvious trigger.

It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the symptoms mentioned above, of which one must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with MDD.

Major Depressive Disorder Diagnosis and Treatment

The treatment strategies for depression consist of pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy and transcranial magnetic stimulation. When the patient prefers psychotherapy, one of the following evidence-based interventions can be offered based on patient preference and availability: Cognitive Behavior Therapy (CBT), Interpersonal Therapy (IPT), Mindfulness-Based Cognitive Therapy (MBCT), Behavioral therapy/behavioral activation (BT/BA), Acceptance and commitment therapy (ACT), and Problem-solving therapy (PST). Selective serotonin reuptake inhibitor (except fluvoxamine), Serotonin-norepinephrine reuptake inhibitor are major classes of therapies prescribed to MDD patients

It covers the details of conventional and current medical therapies and diagnoses available in the Major Depressive Disorder market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States.

The DelveInsight Major Depressive Disorder market report thoroughly understands Major Depressive Disorder symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Major Depressive Disorder symptoms of treatment algorithms and treatment guidelines for Major Depressive Disorder symptoms in the 7MM.

Major Depressive Disorder Epidemiology

The epidemiology division's Major Depressive Disorder symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Major Depressive Disorder epidemiology segmented as the 12 months prevalent cases of Major Depressive Disorder, Gender-specific prevalent case of Major Depressive Disorder, Severity-specific prevalent cases of Major Depressive Disorder and Relapsed/refractory cases of Major Depressive Disorder. The report includes the prevalent scenario of Major Depressive Disorder symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Major Depressive Disorder (MDD) Epidemiology

The epidemiology segment also provides the Major Depressive Disorder (MDD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Major Depressive Disorder in the 7MM were 43,845,330 in 2020.

Major Depressive Disorder Drug Chapters

The drug chapter segment of the Major Depressive Disorder report encloses the detailed analysis of Major Depressive Disorder marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Major Depressive Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines are increasingly recommending psychotherapy as a monotherapy or in combination with antidepressants.

Products detail in the report…

Major Depressive Disorder Emerging Drugs

AXS-05 (dextromethorphan-bupropion) is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development to treat the major depressive disorder and another central nervous system (CNS) disorders. AXS-05 utilizes a proprietary formulation and dose of dextromethorphan and bupropion and Axsome's metabolic inhibition technology to modulate the delivery of the components. The US Food and Drug Administration has accepted company's New Drug Application for AXS-05 for the treatment of the major depressive disorder and has granted the application Priority Review.

Major Depressive Disorder Market Outlook

The Major Depressive Disorder market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Major Depressive Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Major Depressive Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.

According to DelveInsight, the Major Depressive Disorder market in the 7MM is expected to change in the study period 2018-2030.

Key Findings

This section includes a glimpse of the Major Depressive Disorder (MDD) market in 7MM. The market size of MDD in the seven major markets was USD 3,960.6 million in 2020, and the market is estimated to increase at a CAGR of 8.91% for the study period (2018-2030).

The United States Market Outlook

This section provides a total of Major Depressive Disorder market size and market size by therapies in the United States.

The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for Major Depressive Disorder are in development, many of which have novel targets and better safety and efficacy profiles. The expected entry of LY03005 and AXS-05 will boost market growth during the forecast period.

EU-5 Countries: Market Outlook

The total Major Depressive Disorder (MDD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Market Outlook

The total Major Depressive Disorder (MDD) market size and market size by therapies in Japan are also mentioned.

Major Depressive Disorder Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. The analysis covers Major Depressive Disorder market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Major Depressive Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Major Depressive Disorder key players involved in developing targeted therapeutics.

Products detail in the report…

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Major Depressive Disorder emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Major Depressive Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Major Depressive Disorder market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Major Depressive Disorder Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Major Depressive Disorder, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Major Depressive Disorder epidemiology and treatment in the United States
  • Additionally, an all-inclusive account of both the current and emerging therapies for Major Depressive Disorder is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Major Depressive Disorder market; historical and forecasted is included in the report, covering drug outreach in the United States
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Major Depressive Disorder market

Report Highlights:

  • In the coming years, Major Depressive Disorder market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Major Depressive Disorder. The launch of emerging therapies will significantly impact the Major Depressive Disorder market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Major Depressive Disorder.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Major Depressive Disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Major Depressive Disorder Pipeline Analysis
  • Major Depressive Disorder Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Major Depressive Disorder Report Key Strengths

  • 10-year Forecast
  • The United States Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

Major Depressive Disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Major Depressive Disorder (MDD) Market share (%) distribution in 2018, and how it would look like in 2030?
  • What would be the Major Depressive Disorder (MDD) total market size and market size by therapies across the 7MM during the forecast period (2018-2030)?
  • What are the market's key findings across 7MM, and which country will have the largest Major Depressive Disorder (MDD) market size during the forecast period (2018-2030)?
  • At what CAGR, the Major Depressive Disorder (MDD) market is expected to grow by 7MM during the forecast period (2018-2030)?
  • What would be the Major Depressive Disorder (MDD) market outlook across the 7MM during the forecast period (2018-2030)?
  • What would be the Major Depressive Disorder (MDD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Major Depressive Disorder (MDD)?
  • What is the historical Major Depressive Disorder (MDD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Major Depressive Disorder(MDD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Major Depressive Disorder (MDD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Major Depressive Disorder (MDD) during the forecast period (2018-2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2018-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Major Depressive Disorder (MDD)?
  • What are the current treatment guidelines for treating Major Depressive Disorder (MDD)?
  • What are the Major Depressive Disorder (MDD) marketed drugs and their MOA, regulatory milestones, product development activities, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Major Depressive Disorder (MDD)?
  • How many therapies are developed by each company for the treatment of Major Depressive Disorder (MDD)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Major Depressive Disorder (MDD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder (MDD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Major Depressive Disorder (MDD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Major Depressive Disorder (MDD)?
  • What are the global historical and forecasted market of Major Depressive Disorder (MDD)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Major Depressive Disorder (MDD) market
  • To understand the future market competition in the Major Depressive Disorder (MDD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder(MDD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Major Depressive Disorder(MDD) market
  • To understand the future market competition in the Major Depressive Disorder (MDD) market

Table of Contents

1 Key Insights

2 Report Introduction

3 Major Depressive Disorder Market Overview at a Glance

  • 3.1 Market Share (%) Distribution of MDD in 2018
  • 3.2 Market Share (%) Distribution of MDD in 2030

4 Executive Summary of Major Depressive Disorder

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Sign and Symptoms
  • 5.3 Types
  • 5.4 Causes
  • 5.5 Pathophysiology of Depression
  • 5.6 Genetic basis of MDD
  • 5.7 Biomarkers
  • 5.8 Diagnosis and severity
    • 5.8.1 The Diagnostic and Statistical Manual of Mental Disorders (DSM)
      • 5.8.1.1 DSM-IV-TR Criteria for MDD
      • 5.8.1.2 DSM-V: Diagnostic Criteria
      • 5.8.1.3 Differential Diagnosis
      • 5.8.1.4 DSM-IV-TR Criteria for Major Depressive Disorder
      • 5.8.1.5 Depression Rating Scale
      • 5.8.1.6 Montgomery-Asberg Depression Rating Scale (MADRS)
      • 5.8.1.7 Depression Rating Scale (DRS)

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 7MM Total 12 months Prevalent Patient Population of Major Depressive Disorder
  • 6.3 The United States
    • 6.3.1 12 Months Prevalent Cases of Major Depressive Disorder in the US
    • 6.3.2 Gender-specific Prevalence of Major Depressive Disorder in the US
    • 6.3.3 Severity-specific Cases of Major Depressive Disorder in the US
    • 6.3.4 Relapse/Refractory Cases of Major Depressive Disorder in the US
  • 6.4 EU5
    • 6.4.1 Germany
      • 6.4.1.1 12 Months Prevalent Cases of Major Depressive Disorder in Germany
      • 6.4.1.2 Gender-specific Prevalence of Major Depressive Disorder in Germany
      • 6.4.1.3 Severity-specific Cases of Major Depressive Disorder in Germany
      • 6.4.1.4 Relapse/Refractory Cases of Major Depressive Disorder in Germany
    • 6.4.2 France
      • 6.4.2.1 12 Months Prevalent Cases of Major Depressive Disorder in France
      • 6.4.2.2 Gender-specific Prevalence of Major Depressive Disorder in France
      • 6.4.2.3 Severity-specific Cases of Major Depressive Disorder in France
      • 6.4.2.4 Relapse/Refractory Cases of Major Depressive Disorder in France
    • 6.4.3 Italy
      • 6.4.3.1 12 Months Prevalent Cases of Major Depressive Disorder in Italy
      • 6.4.3.2 Gender-specific Prevalence of Major Depressive Disorder in Italy
      • 6.4.3.3 Severity-specific Cases of Major Depressive Disorder in Italy
      • 6.4.3.4 Relapse/Refractory Cases of Major Depressive Disorder in Italy
    • 6.4.4 Spain
      • 6.4.4.1 12 Months Prevalent Cases of Major Depressive Disorder in Spain
      • 6.4.4.2 Gender-specific Prevalence of Major Depressive Disorder in Spain
      • 6.4.4.3 Severity-specific Cases of Major Depressive Disorder in Spain
      • 6.4.4.4 Relapse/Refractory Cases of Major Depressive Disorder in Spain
    • 6.4.5 United Kingdom
      • 6.4.5.1 12 Months Prevalent Cases of Major Depressive Disorder in the UK
      • 6.4.5.2 Gender-specific Prevalence of Major Depressive Disorder in the UK
      • 6.4.5.3 Severity-specific Cases of Major Depressive Disorder in the UK
      • 6.4.5.4 Relapse/Refractory Cases of Major Depressive Disorder in the UK
  • 6.5 Japan
    • 6.5.1 12 Months Prevalent Cases of Major Depressive Disorder in Japan
    • 6.5.2 Gender-specific Prevalence of Major Depressive Disorder in Japan
    • 6.5.3 Severity-specific Cases of Major Depressive Disorder in Japan
    • 6.5.4 Relapse/Refractory Cases of Major Depressive Disorder in Japan

7 Treatment and Management

  • 7.1 American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder
  • 7.2 Major Depressive Disorder Treatment Guidelines in the US and Europe
  • 7.3 Guidelines in Spanish SHN for the Management of Major Depression in Adults
  • 7.4 Major Depressive Disorder Treatment Guidelines in Japan
  • 7.5 Major depressive disorder - Clinical practice review
  • 7.6 Treatment Options for Adults
  • 7.7 Treatment Options for Children and Adolescents
  • 7.8 Treatment Options for Late-Life (Older Adults)
  • 7.9 Algorithm for the Management of Major Depressive Disorder
  • 7.1 Algorithm for the Pharmacotherapy of MDD

8 Organizations contributing towards MDD

9 Patient Journey

10 Case Report

11 Marketed Therapies

  • 11.1 Key cross competition - Marketed Drugs
  • 11.2 Brintellix: Takeda Pharmaceuticals
    • 11.2.1 Product Description
    • 11.2.2 Regulatory Milestones
    • 11.2.3 Clinical Development
    • 11.2.4 Clinical Trials Information
    • 11.2.5 Safety and Efficacy
    • 11.2.6 Product Profile
  • 11.3 Fetzima: Forest Laboratories
    • 11.3.1 Product Description
    • 11.3.2 Pharmacokinetics
    • 11.3.3 Regulatory Milestones
    • 11.3.4 Clinical Development
    • 11.3.5 Clinical Trials Information
    • 11.3.6 Safety and Efficacy
    • 11.3.7 Product Profile
  • 11.4 Rexulti: Otsuka Pharmaceuticals
    • 11.4.1 Product Description
    • 11.4.2 Pharmacokinetics
    • 11.4.3 Regulatory Milestones
    • 11.4.4 Clinical Development
    • 11.4.5 Clinical Trials Information
    • 11.4.6 Safety and Efficacy
    • 11.4.7 Product Profile
  • 11.5 SPRAVATO (Esketamine): Janssen Research & Development
    • 11.5.1 Product Description
    • 11.5.2 Regulatory Milestones
    • 11.5.3 Clinical Development
    • 11.5.4 Clinical Trials Information
    • 11.5.5 Safety and Efficacy
    • 11.5.6 Product Profile

12 Emerging Therapies

  • 12.1 AXS-05: Axsome Therapeutics
    • 12.1.1 Drug Description
    • 12.1.2 Regulatory Milestones
    • 12.1.3 Clinical Development
    • 12.1.4 Clinical Trials Information
    • 12.1.5 Safety and Efficacy
    • 12.1.6 Product Profile
  • 12.2 Travivo: Fabre-Kramer Pharmaceuticals
    • 12.2.1 Drug Description
    • 12.2.2 Regulatory Milestones
    • 12.2.3 Clinical Development
    • 12.2.4 Product Profile
  • 12.3 SAGE-217: SAGE Therapeutics
    • 12.3.1 Drug Description
    • 12.3.2 Regulatory Milestones
    • 12.3.3 Clinical Development
    • 12.3.4 Clinical Trials Information
    • 12.3.5 Safety and Efficacy
    • 12.3.6 Product Profile
  • 12.4 VRAYLAR (Cariprazine): Allergan/Gedeon Richter
    • 12.4.1 Drug Description
    • 12.4.2 Regulatory Milestones
    • 12.4.3 Clinical Development
    • 12.4.4 Clinical Trials Information
    • 12.4.5 Safety and Efficacy
    • 12.4.6 Product Profile
  • 12.5 CTC-501: Chase Therapeutics
    • 12.5.1 Drug Description
    • 12.5.2 Regulatory Milestones
    • 12.5.3 Clinical Development
    • 12.5.4 Clinical Trials Information
    • 12.5.5 Product Profile
  • 12.6 LY03005: Luye Pharma
    • 12.6.1 Drug Description
    • 12.6.2 Regulatory Milestones
    • 12.6.3 Clinical Development
    • 12.6.4 Clinical Trials Information
    • 12.6.5 Product Profile
  • 12.7 MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences
    • 12.7.1 Drug Description
    • 12.7.2 Regulatory Milestones
    • 12.7.3 Clinical Development
    • 12.7.4 Clinical Trials Information
    • 12.7.5 Safety and Efficacy
    • 12.7.6 Product Profile
  • 12.8 REL-1017: Relmada Therapeutics
    • 12.8.1 Drug Description
    • 12.8.2 Regulatory Milestones
    • 12.8.3 Clinical Development
    • 12.8.4 Clinical Trials Information
    • 12.8.5 Product Profile
  • 12.9 PRAX-114: Praxis Precision Medicines
    • 12.9.1 Drug Description
    • 12.9.2 Clinical Development
    • 12.9.3 Clinical Trials Information
    • 12.9.4 Safety and Efficacy
    • 12.9.5 Product Profile
  • 12.1 PDC-1421: BioLite Inc
    • 12.10.1 Drug Description
    • 12.10.2 Regulatory Milestones
    • 12.10.3 Clinical Development
    • 12.10.4 Clinical Trials Information
    • 12.10.5 Product Profile
  • 12.11 PH10: VistaGen Therapeutics
    • 12.11.1 Drug Description
    • 12.11.2 Mechanism of Action
    • 12.11.3 Regulatory Milestones
    • 12.11.4 Safety and Efficacy
    • 12.11.5 Product Profile
  • 12.12 AV-101: VistaGen Therapeutics
    • 12.12.1 Drug Description
    • 12.12.2 Regulatory Milestones
    • 12.12.3 Clinical Development
    • 12.12.4 Clinical Trials Information
    • 12.12.5 Product Profile
  • 12.13 CAPLYTA (Lumateperone): Intra-Cellular Therapies
    • 12.13.1 Drug Description
    • 12.13.2 Clinical Development
    • 12.13.3 Clinical Trials Information
    • 12.13.4 Product Profile

13 Discontinued Therapies

  • 13.1 Pimavanserin: Acadia Pharmaceuticals
    • 13.1.1 Drug Description
    • 13.1.2 Mechanism of Action
    • 13.1.3 Clinical Development
    • 13.1.4 Clinical Trials Information
    • 13.1.5 Product Profile
  • 13.2 Rapastinel: Naurex (Allergan)
    • 13.2.1 Drug Description
    • 13.2.2 Regulatory Milestones
    • 13.2.3 Clinical Development
    • 13.2.4 Clinical Trials Information
    • 13.2.5 Safety and Efficacy
    • 13.2.6 Product Profile

14 No Development Reported

  • 14.1 ALKS 5461: Alkermes
    • 14.1.1 Drug Description
    • 14.1.2 Regulatory Milestones
    • 14.1.3 Clinical Development
    • 14.1.4 Clinical Trials Information
    • 14.1.5 Safety and Efficacy
    • 14.1.6 Product Profile
  • 14.2 NRX-1074 (Apimostinel): Allergen
    • 14.2.1 Drug Description
    • 14.2.2 Regulatory Milestones
    • 14.2.3 Clinical Development
    • 14.2.4 Clinical Trials Information
    • 14.2.5 Product Profile

15 Major Depressive Disorder: Seven Major Market Analysis

  • 15.1 Key Findings
  • 15.2 Market Size of Major Depressive Disorder in the 7MM

16 Market Outlook by Country

  • 16.1 The United States: Market Outlook
  • 16.2 United States Market Size
    • 16.2.1 Total Market Size of Major Depressive Disorder by Class in the US
    • 16.2.2 Market Size of Major Depressive Disorder by Emerging therapies in the US
  • 16.3 EU-5: Market Outlook
    • 16.3.1 Germany
      • 16.3.1.1 Total Market size of Major Depressive Disorder by Class
      • 16.3.1.2 Market Size of Major Depressive Disorder by Emerging therapies in Germany
    • 16.3.2 France
      • 16.3.2.1 Total Market size of Major Depressive Disorder by Class
      • 16.3.2.2 Market Size of Major Depressive Disorder by Emerging therapies in France
    • 16.3.3 Italy
      • 16.3.3.1 Total Market size of Major Depressive Disorder by Class
      • 16.3.3.2 Market Size of Major Depressive Disorder by Emerging therapies in Italy
    • 16.3.4 Spain
      • 16.3.4.1 Total Market size of Major Depressive Disorder by Class
      • 16.3.4.2 Market Size of Major Depressive Disorder by Emerging therapies in Spain
    • 16.3.5 United Kingdom
      • 16.3.5.1 Total Market size of Major Depressive Disorder by Class
      • 16.3.5.2 Market Size of Major Depressive Disorder by Emerging therapies in the UK
  • 16.4 Japan: Market Outlook
    • 16.4.1 Total Market size of Major Depressive Disorder by Class
    • 16.4.2 Market Size of Major Depressive Disorder by Therapies in Japan

17 Market Drivers

18 Market Barriers

19 SWOT Analysis

20 Unmet Needs

21 Market Access

22 Appendix

  • 22.1 Bibliography
  • 22.2 Report Methodology

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

List of Tables

  • Table 1: Summary of Major Depressive Disorder, Market, Epidemiology, and Key Events (2018-2030)
  • Table 2: Assessing the severity of depression
  • Table 3: DSM-IV-TR diagnostic criteria - MDD
  • Table 4: DSM-IV-TR diagnostic criteria for MDD, Single episode
  • Table 5: DSM-IV-TR diagnostic criteria for MDD, Recurrent
  • Table 6: Selected DSM-IV-TR Major Depressive Episode Specifier
  • Table 7: Major depressive disorder diagnostic criteria according to DSM-V
  • Table 8: General Diagnostic Criteria of a Depressive episode according to ICD-10
  • Table 9: Severity Criteria of a Depressive episode according to ICD-10
  • Table 10: 12 Months Prevalent Patient Population of MDD in the 7MM in thousands (2018-2030)
  • Table 11: 12 Months Prevalent Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Table 12: Gender-specific Prevalence of Major Depressive Disorder in the US in thousands (2018-2030)
  • Table 13: Severity-specific Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Table 15: 12 Months Prevalent Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Table 16: Gender-specific Prevalence of Major Depressive Disorder in Germany in Thousands (2018-2030)
  • Table 17: Severity-specific Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Table 18: Relapse/Refractory Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Table 19: 12 Months Prevalent Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Table 20: Gender-specific Prevalence of Major Depressive Disorder in France in thousands (2018-2030)
  • Table 21: Severity-specific Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Table 22: Relapse/Refractory Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Table 23: 12 Months Prevalent Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Table 24: Gender-specific Prevalence of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Table 25: Severity-specific Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Table 26: Relapse/Refractory Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Table 27: 12 Months Prevalent Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Table 28: Gender-specific Prevalence of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Table 29: Severity-specific Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Table 30: Relapse/Refractory Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Table 31: 12 Months Prevalent Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Table 32: Gender-specific Prevalence of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Table 33: Severity-specific Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Table 34: Relapse/Refractory Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Table 35: 12 Months Prevalent Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Table 36: Gender-specific Prevalence of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Table 37: Severity-specific Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Table 38: Relapse/Refractory Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Table 39: Organizations contributing towards MDD
  • Table 40: Key Cross Competition - Marketed Drugs
  • Table 41: Vortioxetine, Clinical Trial Description, 2021
  • Table 42: Levomilnacipran ER, Clinical Trial Description, 2021
  • Table 43: Rexulti, Clinical Trial Description, 2021
  • Table 44: Esketamine, Clinical Trial Description, 2021
  • Table 45: AXS-05, Clinical Trial Description, 2021
  • Table 46: SAGE-217, Clinical Trial Description, 2021
  • Table 47: Cariprazine, Clinical Trial Description, 2021
  • Table 48: CTC-501, Clinical Trial Description, 2021
  • Table 49: LY03005, Clinical Trial Description, 2021
  • Table 50: MIN-202, Clinical Trial Description, 2021
  • Table 51: REL-1017, Clinical Trial Description, 2021
  • Table 52: PRAX-114, Clinical Trial Description, 2021
  • Table 53: PDC-1421, Clinical Trial Description, 2021
  • Table 54: AV-101, Clinical Trial Description, 2021
  • Table 55: Lumateperone, Clinical Trial Description, 2021
  • Table 56: Pimavanserin, Clinical Trial Description, 2021
  • Table 57: Rapastinel, Clinical Trial Description, 2021
  • Table 58: ALKS 5461, Clinical Trial Description, 2021
  • Table 59: NRX-1074, Clinical Trial Description, 2021
  • Table 60: Seven Major Market Size of Major Depressive Disorder in USD Million (2018-2030)
  • Table 61: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 62: The US Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 63: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 64: Germany Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 65: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 66: France Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 67: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 68: Italy Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 69: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 70: Spain Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 71: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 72: The UK Market Size of Major Depressive Disorder by Emerging therapies in USD Million (2018-2030)
  • Table 73: Market Size of Major Depressive Disorder by Class in USD Million (2018-2030)
  • Table 74: Japan Market Size of Major Depressive Disorder by Therapies in USD Million (2018-2030)

List of Figures

  • Figure 1: Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder
  • Figure 2: 12 Months Prevalent Patient Population of MDD in the 7MM in thousands (2018-2030)
  • Figure 3: 12 Months Prevalent Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Figure 4: Gender-specific Prevalence of Major Depressive Disorder in the US in thousands (2018-2030)
  • Figure 5: Severity-specific Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Figure 6: Relapse/Refractory Cases of Major Depressive Disorder in the US in thousands (2018-2030)
  • Figure 7: 12 Months Prevalent Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Figure 8: Gender-specific Prevalence of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Figure 9: Severity-specific Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Figure 10: Relapse/Refractory Cases of Major Depressive Disorder in Germany in thousands (2018-2030)
  • Figure 11: 12 Months Prevalent Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Figure 12: Gender-specific Prevalence of Major Depressive Disorder in France in thousands (2018-2030)
  • Figure 13: Severity-specific Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Figure 14: Relapse/Refractory Cases of Major Depressive Disorder in France in thousands (2018-2030)
  • Figure 15: 12 Months Prevalent Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Figure 16: Gender-specific Prevalence of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Figure 17: Severity-specific Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Figure 18: Relapse/Refractory Cases of Major Depressive Disorder in Italy in thousands (2018-2030)
  • Figure 19: 12 Months Prevalent Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Figure 20: Gender-specific Prevalence of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Figure 21: Severity-specific Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Figure 22: Relapse/Refractory Cases of Major Depressive Disorder in Spain in thousands (2018-2030)
  • Figure 23: 12 Months Prevalent Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Figure 24: Gender-specific Prevalence of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Figure 25: Severity-specific Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in the UK in thousands (2018-2030)
  • Figure 27: 12 Months Prevalent Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Figure 28: Gender-specific Prevalence of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Figure 29: Severity-specific Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Figure 30: Relapse/Refractory Cases of Major Depressive Disorder in Japan in thousands (2018-2030)
  • Figure 31: Basic Principles of Depression Treatment in American and European Guidelines
  • Figure 32: Seven Major Market Size of Major Depressive Disorder in USD Million (2018-2030)
  • Figure 33: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 34: The US Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 35: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 36: Germany Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 37: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 38: France Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 39: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 40: Italy Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 41: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 42: The United States Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 43: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 44: The UK Market Size of Major Depressive Disorder by Emerging therapies in USD Million
  • Figure 45: Market Size of Major Depressive Disorder by Class, USD Million (2018-2030)
  • Figure 46: Japan Market Size of Major Depressive Disorder by Therapies in USD Million(2018-2030)